<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Dermatol</journal-id><journal-id journal-id-type="publisher-id">IJD</journal-id><journal-title-group><journal-title>Indian Journal of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0019-5154</issn><issn pub-type="epub">1998-3611</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25657417</article-id><article-id pub-id-type="pmc">4318023</article-id><article-id pub-id-type="publisher-id">IJD-60-102d</article-id><article-id pub-id-type="doi">10.4103/0019-5154.147835</article-id><article-categories><subj-group subj-group-type="heading"><subject>E-IJD Therapeutic Round</subject></subj-group></article-categories><title-group><article-title>Topical Adapalene in the Treatment of Plantar Warts; Randomized Comparative Open Trial in Comparison with Cryo-Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Ramji</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Sarthak</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1"><italic>From the Department of Dermatology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India</italic></aff><aff id="aff2"><label>1</label><italic>Department of Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health, Bethesda, Maryland, USA</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence:</bold> Dr. Ramji Gupta, M-54, Jal Vihar Road, Lajpat Nagar-II, New Delhi - 110 024, India. E-mail: <email xlink:href="drramjigupta@yahoo.co.in">drramjigupta@yahoo.co.in</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>60</volume><issue>1</issue><fpage seq="d">102</fpage><lpage>102</lpage><history><date date-type="received"><month>9</month><year>2013</year></date><date date-type="accepted"><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Dermatology</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Various therapeutic modalities, which are available for treating plantar wart, have not been successful every time.</p></sec><sec id="st2"><title>Aims:</title><p>To evaluate topical adapalene under occlusion in the treatment of plantar warts and compare it with cryo-therapy.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>50 patients with 424 plantar warts were included in this single center, two arm, prospective, randomized, control, open study. Patients were allocated randomly into two groups consisting of 25 patients each. Group A patients having 299 plantar warts were treated using adapalene gel 0.1% under occlusion while Group B patients having 125 warts were treated using cryo-therapy. All the patients were evaluated weekly till the clearance of all the warts and the results compared.</p></sec><sec id="st4"><title>Result:</title><p>All the warts of 25 patients of Group A that were treated using adapalene gel 0.1% cleared in 36.71 &#x000b1; 19.24 (55.95-17.47) days except those in one patient. In Group B, warts in all except one treated by cryo-therapy cleared in 52.17 &#x000b1; 30.06 (82.23-22.11) days. There were no side effects like scar formation, irritation, erythema, or infections with adapalene group while in the cryo group scar was seen in 2 patients, pain in 24, erythema in 10, and infection in 3 patients.</p></sec><sec id="st5"><title>Conclusion:</title><p>Adapalene gel 0.1% under occlusion is an effective, safe and easy to use treatment for plantar warts and may help clear lesions faster than cryo-therapy.</p></sec></abstract><kwd-group><kwd><italic>Adapalene</italic></kwd><kwd><italic>cryo-therapy</italic></kwd><kwd><italic>occlusion</italic></kwd><kwd><italic>plantar wart</italic></kwd></kwd-group></article-meta></front><body><boxed-text position="float"><p><bold>What was known?</bold></p><p>Treatment result of plantar warts is not uniform.</p></boxed-text><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Treatment of plantar warts, which are caused by human papilloma virus (HPV) type 1, 2, and 4, is often challenging. Various therapeutic modalities that have been used for treating it have not been successful every time.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>]</p><p>Adapalene, a synthetic naphthoic acid derivative, is very commonly used in the treatment of mild-to-moderate acne.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] It is available as 0.1% aqueous gel. It is a retinoid with ability to alter keratinization and affinity for retinoic acid receptor (RARY).[<xref rid="ref7" ref-type="bibr">7</xref>] It is found predominantly in the epidermis. It has been found to have anti-inflammatory action, inhibits cell proliferation, and modulates cell differentiation.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] After successful treatment of 10 patients with a total 118 warts, with topical adapalene 0.1% gel, with occlusion,[<xref rid="ref10" ref-type="bibr">10</xref>] subsequently we studied it in a larger number of patients in a prospective, randomized, control, open trial in comparison with cryo therapy. Data on 50 patients were randomly allocated into two groups, one group was treated with 0.1% adapalene gel under occlusion and the other group with cryo-therapy[<xref rid="ref11" ref-type="bibr">11</xref>] are presented. Time taken to complete clearance of lesions was compared between the two groups.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>Fifty patients with 424 plantar warts were included in this single center, two arm, prospective, randomized, control, and open study. Diagnosis of plantar warts was made based on clinical presentation like rough surface, well-defined border [<xref ref-type="fig" rid="F1">Figure 1</xref>] and pain on pressure. Informed consent was taken from all the patients after explaining in details about the purpose and procedure of the treatment. Healthy patients with plantar warts were included in the study. Those patients who were on any systemic therapy in the past 8 weeks and pregnant women were excluded from the study. All topical treatment was stopped 4 weeks prior to the study. Patients were randomly allocated into two treatment groups: Group A (Adapalene 0.1% gel) and Group B (cryo- therapy, very commonly used therapy for plantar warts in this part of country). Comparison was not done with placebo due to fear that many patients may drop during follow-up due to ineffectiveness. All the odd numbered patients, who came to the outpatient department, were allocated to Group A, while all the even numbered patients were allocated to Group B. Thus, 25 patients who were allocated to Group A were treated with topical adapalene 0.1% gel applied twice daily under occlusion using plastic wrap while another 25 patients who were allocated to Group B were treated with cryo-therapy for1-2 minutes using N<sub>2</sub>O gas operated machine with &#x02212;94&#x000b0;C temperature. Cryo-therapy was repeated within 2 weeks, if there were no signs of improvements in the form of reduction in the pain and/or development of black spots. Once there was improvement, they were followed up for clearance without any cryo sitting. In both the groups, hyperkeratosis or thick areas were pared before doing cryo-therapy or applying adapalene gel. Thus paring was done initially during treatment. The treatment was continued till the clearance of all the warts [<xref ref-type="fig" rid="F2">Figure 2</xref>] in both the groups. The effect of treatment was evaluated weekly till the clearance of all the warts, followed by monthly evaluation for at least 6 months for any recurrences.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Plantar warts before treatment</p></caption><graphic xlink:href="IJD-60-102d-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Plantar warts after treatment</p></caption><graphic xlink:href="IJD-60-102d-g002"/></fig><sec id="sec2-1"><title/><sec id="sec3-1"><title>Statistical analysis</title><p>A test of significance using Student's <italic>t</italic>-test was employed to see the efficacy of both the treatments in terms of duration of clearance of warts. At 9 degrees of freedom and 5% level of significance it was found that there was a significant difference between both treatment regimes. On the basis of limited data, it was found that use of treatment regime of adapalene (0.1%) with occlusion has reduced duration of clearance of warts in these patients (<italic>P</italic> &#x0003c; 0.05).</p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>Fifty patients (M-26, F-24) with 424 warts were enrolled in this study. The mean age of all the patients was 27.56 (13-55) years and the mean duration of the warts was 8.31 months. One patient in each group was lost to follow-up. In Group A, all the warts in 24 patients disappeared in 36.71 &#x000b1; 19.24 days [<xref ref-type="table" rid="T1">Table 1</xref>]. In Group B, all the warts in 24 patients disappeared in 52.17 &#x000b1; 30.06 days [<xref ref-type="table" rid="T2">Table 2</xref>] in an average of 1.88 (1-4) sittings of cryo-therapy.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Detail of patients treated by adapalene gel 0.1% under occlusion</p></caption><graphic xlink:href="IJD-60-102d-g003"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Detail of patients treated by cryo-therapy</p></caption><graphic xlink:href="IJD-60-102d-g004"/></table-wrap><p>There was no recurrence in any patient followed up for an average of 8.47 months.</p><p>On comparison of each group [<xref ref-type="table" rid="T3">Table 3</xref>], patients in Group A, treated with adapalene with occlusion, achieved complete clearance of their lesions sooner than patients in Group B, treated with cryo-therapy.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of treatment by adapalene gel 0.1% and cryo-therapy</p></caption><graphic xlink:href="IJD-60-102d-g005"/></table-wrap><sec id="sec2-2"><title/><sec id="sec3-2"><title>Side effects</title><p>There was no side effect like irritation, erythema, infection, or scar formation in any patient treated by adapalene gel. However, patients of the cryo group developed scar in 2 patients, pain in all 24 patients, erythema in 10 patients, and infection in 3 patients.</p></sec></sec></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>Various immuno-modulating agents used for treatments of warts include oral cimetidine and levamisole,[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] intralesional BCG vaccines, interferon, and imiquimod.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] The aim of using immuno-therapy is to hasten the clearance of warts although the mechanism is still not clear. One theory suggests induction of a type IV hypersensitivity reaction another suggesting that the substance acts as a hapten to wart virus proteins to induce an immune reaction to HPV.</p><p>In a comparative study by Parsad <italic>et al</italic>.[<xref rid="ref13" ref-type="bibr">13</xref>] oral cimetidine was able to clear lesions in 11 weeks in 31.5% of cases only where as cimetidine + levamisole took 7.8 weeks. Imiquimod, another immuno-modulator, was reported to clear the plantar warts when used with occlusion in 12 weeks.[<xref rid="ref14" ref-type="bibr">14</xref>] Gelmetti <italic>et al</italic>.[<xref rid="ref17" ref-type="bibr">17</xref>] used etretinate 1 mg/kg/day orally, in 20 children, for 3 months with extensive warts. Sixteen children showed complete regression, without relapse, while in 4, lesions relapsed after initial regression. Choi <italic>et al</italic>.[<xref rid="ref18" ref-type="bibr">18</xref>] used acitretin 0.5 mg/kg body weight/day orally for 3 months in an extensive and recalcitrant wart with complete clearance of the lesion. Euvrard <italic>et al</italic>.[<xref rid="ref19" ref-type="bibr">19</xref>] were the first to use topical retinoid in warts, in a transplant recipient patient, with good result.</p><p>In the present study, use of topical adapalene aqueous gel 0.1% under occlusion resulted in complete clearance of 286 plantar warts in 24 patients in 36.71 &#x000b1; 19.24 days while 124 warts in 24 patients treated with cryo-therapy took 52.17 &#x000b1; 30.06 days (<italic>P</italic> &#x0003c; 0.05). Thus adapalene gel 0.1% under occlusion is more effective than cryo-therapy in the treatment of plantar warts. There are several advantages of using adapalene over cryo-therapy. Adapalene, besides clearing the warts fast, also has no side effects. It is simple and convenient to apply.</p><p>In conclusion, topical adapalene under occlusion seems to be an effective, simple, and convenient to apply and safe modality of therapy for treatment of plantar warts and may help clear wart lesions sooner when compared to cryo-therapy. However, with topical adapalene, the patient has to use plastic occlusion daily which may be messy and may not be liked by some patients. It also needs confirmation by further study by more workers as it is the first study of its kind.</p><boxed-text position="float"><p><bold>What is new?</bold></p><p>Adapalene a new compound is able to clear the plantar warts fast without any side effect.</p></boxed-text></sec></body><back><ack><title>Acknowledgement</title><p>The author thanks Mr. Anil Gupta, Center for Social Medicine and Community Health, Jawaharlal Nehru University, New Delhi, India for statistical assistance.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> Nil.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>S</given-names></name><name><surname>Harvey</surname><given-names>I</given-names></name><name><surname>Sterling</surname><given-names>J</given-names></name><name><surname>Stark</surname><given-names>R</given-names></name></person-group><article-title>Local treatments for cutaneous warts: Systematic review</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>461</fpage><pub-id pub-id-type="pmid">12202325</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacelieri</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>SM</given-names></name></person-group><article-title>Cutaneous warts: An evidence-based approach to therapy</article-title><source>Am Fam Physician</source><year>2005</year><volume>72</volume><fpage>647</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16127954</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterling</surname><given-names>JC</given-names></name><name><surname>Handfield-Jones</surname><given-names>S</given-names></name><name><surname>Hudson</surname><given-names>PM</given-names></name></person-group><article-title>Guidelines for the management of cutaneous warts</article-title><source>Br J Dermatol</source><year>2001</year><volume>144</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11167676</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>CS</given-names></name><name><surname>Gibbs</surname><given-names>S</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Holland</surname><given-names>R</given-names></name><name><surname>Abbott</surname><given-names>R</given-names></name></person-group><article-title>Topical treatments for cutaneous warts</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>9</volume><fpage>CD001781</fpage><pub-id pub-id-type="pmid">22972052</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brogden</surname><given-names>RN</given-names></name><name><surname>Goa</surname><given-names>KE</given-names></name></person-group><article-title>Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne</article-title><source>Drugs</source><year>1997</year><volume>53</volume><fpage>511</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9074847</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalita</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>JS</given-names></name><name><surname>Chalker</surname><given-names>DK</given-names></name><name><surname>Ellis</surname><given-names>CN</given-names></name><name><surname>Greenspan</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>HI</given-names></name><etal/></person-group><article-title>A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial</article-title><source>J Am Acad Dermatol</source><year>1996</year><volume>34</volume><fpage>482</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8609263</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>BA</given-names></name></person-group><article-title>Adapalene, a new chemical entity with retinoid activity</article-title><source>Skin Pharmacol</source><year>1993</year><volume>6</volume><issue>Suppl 1</issue><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8142113</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensby</surname><given-names>C</given-names></name><name><surname>Cavey</surname><given-names>D</given-names></name><name><surname>Bouclier</surname><given-names>M</given-names></name><name><surname>chatelus</surname><given-names>A</given-names></name><name><surname>Algate</surname><given-names>D</given-names></name><name><surname>Eustache</surname><given-names>J</given-names></name><etal/></person-group><article-title>The <italic>in vivo</italic> and <italic>in vitro</italic> anti-inflammatory activity of CD271: A new retinoid-like modulator of cell differentiation</article-title><source>Agents Actions</source><year>1990</year><volume>29</volume><fpage>56</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2109510</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselineau</surname><given-names>D</given-names></name><name><surname>Cavey</surname><given-names>MT</given-names></name><name><surname>Shroot</surname><given-names>B</given-names></name><name><surname>Darmon</surname><given-names>M</given-names></name></person-group><article-title>Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP)</article-title><source>J Invest Dermatol</source><year>1992</year><volume>98</volume><fpage>128</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">1370673</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R</given-names></name></person-group><article-title>Plantar warts treated with topical adapalene</article-title><source>Indian J Dermatol</source><year>2011</year><volume>56</volume><fpage>513</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22121266</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limmer</surname><given-names>BL</given-names></name><name><surname>Bogy</surname><given-names>LT</given-names></name></person-group><article-title>Cryosurgery of plantar warts</article-title><source>J Am Podiatry Assoc</source><year>1979</year><volume>69</volume><fpage>713</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">521593</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saul</surname><given-names>A</given-names></name><name><surname>Sanz</surname><given-names>R</given-names></name><name><surname>Gomez</surname><given-names>M</given-names></name></person-group><article-title>Treatment of multiple viral warts with levamisole</article-title><source>Int J Dermatol</source><year>1980</year><volume>19</volume><fpage>342</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7005134</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsad</surname><given-names>D</given-names></name><name><surname>Saini</surname><given-names>R</given-names></name><name><surname>Negi</surname><given-names>KS</given-names></name></person-group><article-title>Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts</article-title><source>Australas J Dermatol</source><year>1999</year><volume>40</volume><fpage>93</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10333620</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>SB</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Ransdell</surname><given-names>BL</given-names></name></person-group><article-title>Plantar wart treatment with combination imiquimod and salicylic acid pads</article-title><source>J Drugs Dermatol</source><year>2003</year><volume>2</volume><fpage>124</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12905977</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzio</surname><given-names>G</given-names></name><name><surname>Massone</surname><given-names>C</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name></person-group><article-title>Treatment of non-genital warts with topical imiquimod 5% cream</article-title><source>Eur J Dermatol</source><year>2002</year><volume>12</volume><fpage>347</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12095879</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grussendorf-Conen</surname><given-names>EI</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children</article-title><source>Pediatr Dermatol</source><year>2002</year><volume>19</volume><fpage>263</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12047649</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelmetti</surname><given-names>C</given-names></name><name><surname>Cerri</surname><given-names>D</given-names></name><name><surname>Schiuma</surname><given-names>AA</given-names></name><name><surname>Menni</surname><given-names>S</given-names></name></person-group><article-title>Treatment of extensive warts with etretinate: A clinical trial in 20 children</article-title><source>Pediatr Dermatol</source><year>1987</year><volume>4</volume><fpage>254</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3321005</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>lee</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Treatment of extensive and recalcitrant viral warts with acitretin</article-title><source>Int J Dermatol</source><year>2006</year><volume>45</volume><fpage>480</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16650187</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Euvrard</surname><given-names>S</given-names></name><name><surname>Verschoore</surname><given-names>M</given-names></name><name><surname>Touraine</surname><given-names>JL</given-names></name><name><surname>Dureau</surname><given-names>G</given-names></name><name><surname>Cochat</surname><given-names>P</given-names></name><name><surname>Czernielewski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Topical retinoids for warts and keratoses in transplant recipients</article-title><source>Lancet</source><year>1992</year><volume>340</volume><fpage>48</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1351617</pub-id></element-citation></ref></ref-list></back></article>